Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: A pilot study

Pharmacogenomics

Volumn 15, Issue 7, 2014, Pages 915-923

  Rossi, Joseph S ^a,b,c   Cammarata, Michael ^a   Dharmavaram, Jayalalitha ^a   Weck, Karen ^a,b   Walko, Christine ^b   Gabriel, Don ^a   Kuritzky, Jack ^a   Muldrew, Kenneth ^d   Stouffer, George A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c St Vincent Medical Group   (United States)

^d UNIVERSITY OF TOLEDO   (United States)

Author keywords

clopidogrel; genetic testing; platelet function; polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG METABOLITE; GENOMIC DNA; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; LOSS OF FUNCTION MUTATION; MALE; OUTPATIENT; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PILOT STUDY; PLATELET REACTIVITY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; ALLELE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; GENETIC SCREENING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOCYTE;

AGED; ALLELES; BLOOD PLATELETS; CYTOCHROME P-450 CYP2C19; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84903118892     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.17     Document Type: Article

References (30)

1. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Udate for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117(2), 261-295 (2008).
2. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123(18), e426-e579 (2011).
3. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
4. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
5. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404-1411 (2008).
6. Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol. 46(10), 1827-1832 (2005).
7. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48(9), 1742-1750 (2006).
8. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25), 3171-3175 (2004).
9. Cuisset T, Frere C, Quilici J et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48(7), 1339-1345 (2006).
10. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110(14), 1916-1919 (2004).
11. Montalescot G, Sideris G, Meuleman C et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48(5), 931-938 (2006).
12. Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007).
13. Oestreich JH, Holt J, Dunn SP et al. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coronary Artery Disease 20(3), 207-213 (2009).
14. Price MJ, Berger PB, Teirstein PS et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097-1105 (2011).
15. von Beckerath N, Kastrati A, Wieczorek A et al. A doubleblind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J. 28(15), 1814-1819 (2007).
16. Mega JL, Hochholzer W, Frelinger AL, 3rd et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306(20), 2221-2228 (2011).
17. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309-317 (2009).
18. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
19. Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51(20), 1925-1934 (2008).
20. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
21. Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA Focused Update Incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-elevation Myocardial Infarction a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 57(19), e215-e367 (2011).
22. Scott SA, Sangkuhl K, Stein CM et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharm. Ther. 94(3), 317-323 (2013).
23. Price MJ, Berger PB, Teirstein PS et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097-1105 (2011).
24. Cattaneo M, Cerletti C, Harrison P et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J. Thromb. Haemost. doi:10.1111/jth.12231 (2013) (Epub ahead of print).
25. Manoukian SV, Feit F, Mehran R et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J. Am. Coll. Cardiol. 49(12), 1362-1368 (2007).
26. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 48(4), 1219-1224 (2008).
27. Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512-518 (2010).
28. Lewis JP, Stephens SH, Horenstein RB et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J. Thromb. Haemost. 11(9), 1640-1646 (2013).
29. Collet JP, Hulot JS, Anzaha G et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2). JACC Cardiovasc. Interv. 4(4), 392-402 (2011).
30. Collet JP, Cuisset T, Range G et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367(22), 2100-2109 (2012).